cis- B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8 + T cell function and anti-tumor immunity
Immunity, ISSN: 1074-7613, Vol: 56, Issue: 6, Page: 1187-1203.e12
2023
- 34Citations
- 58Captures
- 8Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations34
- Citation Indexes34
- 34
- CrossRef22
- Captures58
- Readers58
- 58
- Mentions8
- News Mentions8
- 8
Most Recent News
Investigators from University of California San Diego (UCSD) Have Reported New Data on Proteomics (Cis-b7:cd28 Interactions At Invaginated Synaptic Membranes Provide Cd28 Co-stimulation and Promote Cd8+t Cell Function and Anti-tumor Immunity)
2023 AUG 07 (NewsRx) -- By a News Reporter-Staff News Editor at Proteomics Daily -- Current study results on Proteomics have been published. According to
Article Description
B7 ligands (CD80 and CD86), expressed by professional antigen-presenting cells (APCs), activate the main co-stimulatory receptor CD28 on T cells in trans. However, in peripheral tissues, APCs expressing B7 ligands are relatively scarce. This raises the questions of whether and how CD28 co-stimulation occurs in peripheral tissues. Here, we report that CD8 + T cells displayed B7 ligands that interacted with CD28 in cis at membrane invaginations of the immunological synapse as a result of membrane remodeling driven by phosphoinositide-3-kinase (PI3K) and sorting-nexin-9 (SNX9). cis- B7:CD28 interactions triggered CD28 signaling through protein kinase C theta (PKCθ) and promoted CD8 + T cell survival, migration, and cytokine production. In mouse tumor models, loss of T cell-intrinsic cis -B7:CD28 interactions decreased intratumoral T cells and accelerated tumor growth. Thus, B7 ligands on CD8 + T cells can evoke cell-autonomous CD28 co-stimulation in cis in peripheral tissues, suggesting cis- signaling as a general mechanism for boosting T cell functionality.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1074761323001735; http://dx.doi.org/10.1016/j.immuni.2023.04.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85161340186&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37160118; https://linkinghub.elsevier.com/retrieve/pii/S1074761323001735; https://dx.doi.org/10.1016/j.immuni.2023.04.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know